Tafoxiparin Labor Induction Without Prostaglandin Hypercontractility

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for inducing labor in term pregnant women, particularly in those with an unfavorable cervix, often result in complications due to hypercontractility and umbilical blood flow issues, necessitating the development of a safer and more effective therapy.

Innovation Solution

Tafoxiparin, a heparin derivative with specific anticoagulant activity and molecular weight characteristics, is administered as monotherapy in daily doses of 30-320 mg to promote spontaneous onset of labor by cervical ripening and myometrial stimulation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If prostaglandins (PGE2 or PGE1) are administered locally to induce labor, then cervical ripening is achieved, but hypercontractility occurs with bad influence on umbilical blood flow

Engineering Contradiction:

Improvecervical ripening effectivenessVSAvoidhypercontractility and umbilical blood flow compromise

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameters of the active substance by using tafoxiparin (a heparin derivative with specific molecular weight 4.6-6.9 kDa and specific disaccharide structure) instead of prostaglandins, thereby achieving cervical ripening without the harmful hypercontractility and umbilical blood flow compromise associated with prostaglandin administration

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces tafoxiparin as an intermediary substance that mediates cervical ripening and labor induction without directly causing the harmful effects of prostaglandins, thus serving as a safer alternative that achieves the desired effect without the adverse side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If exogenous oxytocin is administered intravenously to induce labor, then uterine contractions are potentiated, but the choice of intervention becomes limited based on cervix ripeness

Engineering Contradiction:

Improvelabor induction effectivenessVSAvoidflexibility in intervention choice

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent makes tafoxiparin a universal agent that can be used across different cervix ripeness stages and labor induction scenarios, providing flexible intervention choice regardless of whether the cervix is ripe or unripe, thus overcoming the limitation of oxytocin which requires cervix ripeness assessment

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Productivity

If mechanical stimulation or oxytocin infusion is used for labor induction, then labor is initiated quickly in ripe cervix, but additional pharmacologic intervention is required for unfavorable cervix

Engineering Contradiction:

Improvelabor initiation speedVSAvoidnumber of interventions required

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent segments the labor induction process into two phases: (1) cervical ripening phase using tafoxiparin for unfavorable cervix, and (2) labor initiation phase using mechanical stimulation or oxytocin for ripe cervix, thereby simplifying the overall intervention strategy by addressing each phase appropriately

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies preliminary action by using tafoxiparin to ripen the cervix before initiating labor with mechanical stimulation or oxytocin, thereby preparing the cervix in advance to enable faster and more effective labor induction without requiring multiple complex interventions

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Tafoxiparin effectively initiates spontaneous labor, reduces the need for instrumental delivery, and minimizes fetal distress by enhancing cervical ripening and myometrial contractions without the side effects associated with traditional interventions.

Implementation Method 1

tafoxiparin, a heparin derivative with specific anticoagulant activity and molecular weight characteristics

Methodology Applied

Scientific EffectAnticoagulant activity:

Implementation Method 2

promote spontaneous onset of labor by cervical ripening and myometrial stimulation

Methodology Applied

Scientific EffectCervical ripening:

Data Source

PatentUS12419904B2Medical use of tafoxiparin

Publication Date: 2025.09.23 DILAFOR

AI summary

The present invention is directed to tafoxiparin for use in the spontaneous onset of labor in a term pregnant woman, wherein tafoxiparin is administered in a daily dose of 30-320 mg per day.